everyone achieves greatness at biontech! as one of the most rapidly growing biotechnology companies in europe, we’re working on revolutionary approaches in the fight against cancer and other diseases. over 400 dedicated, passionate pioneers achieve sensational success and promising breakthroughs time and again by forging new paths – and ensure people all around the world have hope for the future. you too can become a pioneer! http://biontech.de/ http://biontech.de/imprint/
Company profile
Ticker
BNTX
Exchange
Website
CEO
Ugur Sahin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
BNTX stock data
Latest filings (excl ownership)
6-K
Invitation to the Annual General Meeting 2024
8 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Current report (foreign)
22 Mar 24
20-F
2023 FY
Annual report (foreign)
20 Mar 24
6-K
BioNTech Announces Fourth Quarter and Full Year 2023
20 Mar 24
6-K
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
20 Mar 24
6-K
BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
11 Mar 24
6-K
BioNTech Announces Planned Retirement of Sean Marett
7 Mar 24
S-8
Registration of securities for employees
15 Feb 24
6-K
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
8 Feb 24
Transcripts
BNTX
Earnings call transcript
2023 Q4
20 Mar 24
BNTX
Earnings call transcript
2023 Q3
6 Nov 23
BNTX
Earnings call transcript
2023 Q2
7 Aug 23
BNTX
Earnings call transcript
2023 Q1
8 May 23
BNTX
Earnings call transcript
2022 Q4
27 Mar 23
BNTX
Earnings call transcript
2022 Q1
9 May 22
BNTX
Earnings call transcript
2021 Q4
30 Mar 22
BNTX
Earnings call transcript
2021 Q3
9 Nov 21
BNTX
Earnings call transcript
2021 Q2
9 Aug 21
BNTX
Earnings call transcript
2021 Q1
10 May 21
Latest ownership filings
144
Notice of proposed sale of securities
28 Feb 24
SC 13D
Autolus Therapeutics plc
21 Feb 24
SC 13G/A
Medine GmbH
14 Feb 24
SC 13G/A
ATHOS KG
7 Feb 24
144
Notice of proposed sale of securities
4 Jan 24
144/A
Notice of proposed sale of securities (amended)
10 Oct 23
144
Notice of proposed sale of securities
29 Sep 23
144
Notice of proposed sale of securities
29 Sep 23
144/A
Notice of proposed sale of securities (amended)
14 Aug 23
144
Notice of proposed sale of securities
29 Jun 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
77.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 252 |
Opened positions | 32 |
Closed positions | 35 |
Increased positions | 68 |
Reduced positions | 73 |
13F shares | Current |
---|---|
Total value | 3.98 tn |
Total shares | 184.64 mm |
Total puts | 1.59 mm |
Total calls | 1.48 mm |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Athos KG | 105.61 mm | $0.00 |
Medine GmbH | 41.41 mm | $0.00 |
Baillie Gifford & Co | 8.60 mm | $934.61 bn |
Primecap Management | 4.63 mm | $503.22 bn |
Temasek | 4.52 mm | $490.84 bn |
Flossbach Von Storch | 3.51 mm | $381.68 bn |
BLK Blackrock | 1.57 mm | $170.98 bn |
Capital World Investors | 924.72 k | $100.46 bn |
Ubs Global Asset Management Americas | 858.14 k | $93.23 bn |
Artisan Partners Limited Partnership | 734.62 k | $79.81 bn |
News
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
23 Apr 24
Assessing BioNTech: Insights From 11 Financial Analysts
17 Apr 24
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $107 Price Target
17 Apr 24
Reported Sunday, BioNTech Three-Year Phase 1 Follow-Up Data For mRNA-based Individualized Immunotherapy Candidate Shows Persistence Of Immune Response And Delayed Tumor Recurrence In Some Patients With Resected Pancreatic Cancer
8 Apr 24
CureVac, GSK Partner Release Data On Influenza Vaccine Study
4 Apr 24
Press releases
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
7 Apr 24
WuXi Biologics Reports Solid 2023 Annual Results
26 Mar 24
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
26 Mar 24
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
20 Mar 24
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
20 Mar 24